Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are Prothrombotic Mutations a Time-to-Event Risk Factor?

Branko V Tomic1, Maja Z Gvozdenov1, Iva B Pruner1

  • 1Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.

Laboratory Medicine
|October 17, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of decreased fibrinolytic activity and plasminogen activator inhibitor-1 4G/5G polymorphism on the risk of venous thrombosis.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2017
Same author

Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention.

Pharmacogenomics·2016
Same author

Thrombin generation, D-dimer and protein S in uncomplicated pregnancy.

Clinical chemistry and laboratory medicine·2015
Same author

Risk factors for thrombosis in Serbian children.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2013
Same author

Rationalized DNA sequencing-based protocol for genotyping patients receiving coumarin therapy.

Scandinavian journal of clinical and laboratory investigation·2013
Same author

Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation.

Journal of thrombosis and thrombolysis·2012

Common genetic mutations like Factor V Leiden and Factor II G20210A do not predict the timing of a first deep vein thrombosis (DVT) in Serbian patients. These prothrombotic mutations show similar prevalence across all age groups studied.

Area of Science:

  • Genetics
  • Hematology
  • Vascular Medicine

Background:

  • Deep vein thrombosis (DVT) is a common disorder influenced by genetic and acquired risk factors.
  • The relative importance of genetic versus acquired risk factors for DVT may change with age.
  • Understanding genetic predispositions is crucial for managing DVT risk across the lifespan.

Purpose of the Study:

  • To investigate the association between common prothrombotic mutations (Factor V Leiden and Factor II G20210A) and the age of first-time DVT.
  • To determine if these genetic factors serve as age-related risk markers for DVT onset.

Main Methods:

  • A retrospective study was conducted on 701 Serbian patients who experienced their first DVT event.
  • Prevalence of Factor V Leiden and Factor II G20210A mutations was analyzed in relation to patient age at diagnosis.
Keywords:
FII G20210AFV Leidenagingdeep venous thrombosisprognostic markerthrombophilia

Related Experiment Videos

Main Results:

  • No statistically significant difference in the prevalence of Factor V Leiden or Factor II G20210A mutations was observed based on patient age.
  • The odds ratios for both mutations indicated no age-related predictive value for DVT occurrence.
  • Mutation prevalence remained consistent across different age groups at the time of the first DVT.

Conclusions:

  • The studied prothrombotic mutations (Factor V Leiden and Factor II G20210A) are not reliable prognostic markers for the timing of a first DVT in the Serbian population.
  • Further research is needed to explore other potential genetic or acquired factors influencing DVT onset across different age demographics.